MedTech Strategist Issue: Vol. 5, No. 16 - November 26, 2018

 

Already a Subscriber?

 

Not a Subscriber?


Perspective - “China and the Value of Speed to Scale”

By David Cassak, Co-Editor-in-Chief

In global economics, is China’s greatest strength irrelevant to the medical device industry?

mathew-schwartz-397471-unsplash.jpg

Steve-Steinhubl---mstops.jpg

Digital Health - “mSToPS: How Digital Wearables Could Enable Less Costly, More Real-World Clinical Trials”

By Mary Thompson, Executive Editor

A Conversation with Steven Steinhubl, MD. As medtech stakeholders debate the best ways to design and implement more cost effective, pragmatic, and patient-centric clinical trials, one recent digital health study that remotely screened high-risk individuals for undiagnosed atrial fibrillation could help provide a roadmap for the future.


Otolaryngology - “Breaking Sound Barriers in the Hearing Aid Market”

By Mary Stuart, Senior Writer/Market Analyst

The market for hearing aids is undergoing upheaval; companies with new direct-to-consumer models and lower-cost devices, and new players from the audio, information technology, and communications industries are set to compete with the medtech manufacturers of premium hearing aids. Will the newcomers create pricing pressure, or will they reach new kinds of customers and grow a significantly underpenetrated market for the treatment of hearing loss?

sound-waves.jpg

Spine Surgery - “At NASS 2018, Advanced Biomaterials and the Pull of Robots”

By Wendy Diller, Senior Writer/Market Analyst

The backdrop for NASS was a chal­lenged marketplace and excitement around robotics, which is seeing grow­ing acceptance, albeit off a small base. Debates continue over the abilities of new biomaterials versus biologics to address gaps in care.


Start-Ups to Watch: Gastroenterology - “Omniscient: Increasing Adenoma Detection Rates during Screening Colonoscopy”

By Mary Stuart, Senior Writer/Market Analyst

Screening colonoscopy has been wildly successful at preventing colorectal cancer, but there is a little-discussed shortcoming: high adenoma miss rates, i.e. cases where patients have precancerous lesions that weren’t found during screening. Omiscient Imaging LLC aims to boost detection rates with a new endoscopic camera that can see forward, backwards, and sideways in one view.


predigen-logo.png

Start-Ups to Watch: Clinical Diagnostics - “Predigen: Predictive Host Response Genomics for Early Diagnosis of Disease”

By Wendy Diller, Senior Writer/Market Analyst

Spun out of the world-renowned Center for Applied Genomics and Precision Medicine at Duke University, Predigen is using molecular technologies to identify and develop novel host response biomarkers that enable rapid, accurate clinical diagnosis and prognosis of infectious diseases, with plans to expand its expertise to more indications in the longer term.


Not a Subscriber?

Already a Subscriber?

Want a Sample Article?


Companies Covered in this Issue:  Aetna Inc.,  Apple Inc., Decibel Therapeutics, Cochlear Ltd., Eargo Inc., Earlens Corp., Fosun International, Globus Medical Inc., GN Store Nord, Google, iHEAR Medical Inc., iRhythm Technologies Inc., Johnson & Johnson, Mazor Robotics, Medtronic PLC, MicroPort Orthopedics Inc., Nuvasive Inc., Omniscient Imaging LLC, Qvella Inc., Predigen Inc., Sonova Holding AG, Starkey Hearing Technologies, Sivantos Pte. Ltd., Stryker Corp., Titan Spine Inc., Widex AS, Wright Medical Group NV, Zimmer Biomet Inc.

Topics Covered in this Issue: Business Strategies; Cardiovascular/Vascular; Critical Care/Emergency Medicine/ICU; Diagnostics; Digital Health; Emerging Markets; Gastroenterology; Imaging; Neurology/Neurovascular; Orthopedics/Spine; Perspective & Commentary; Regulatory & Reimbursement; Respiratory/ENT; Start-Ups; Surgery/Robotics